Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 12 28 51 14
Erectile Dysfunction 12 51 40 69
Erectile Dysfunction Adverse Event 69
Sexual Impotence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1875

Summaries for Impotence

MedlinePlus : 40 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and gynecomastia, and has symptoms including unable to perform sex, inability to maintain erection and equilibration disorder. An important gene associated with Impotence is NOS1 (Nitric Oxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Relaxin signaling pathway. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include prostate, spinal cord and bone, and related phenotype is reproductive system.

Wikipedia : 72 Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the... more...

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 33.3 ALDH7A1 NOS3 PDE5A
2 gynecomastia 30.1 KLK3 PRL SHBG
3 varicocele 29.7 NOS2 NOS3 PRL SHBG
4 vascular disease 29.3 EDN1 KNG1 NOS2 NOS3
5 diabetic neuropathy 11.2
6 amyloidosis, hereditary, transthyretin-related 10.9
7 neuropathy, hereditary sensory and autonomic, type iii 10.9
8 empty sella syndrome 10.9
9 autonomic dysfunction 10.9
10 dysautonomia 10.9
11 multiple system atrophy with orthostatic hypotension 10.9
12 platelet membrane fluidity 10.4 NOS2 NOS3
13 psychosexual disorder 10.4 PDE5A SHBG
14 prinzmetal's variant angina 10.3 EDN1 NOS3
15 cluster headache 10.3 NOS1 VIP
16 tetrahydrobiopterin deficiency 10.3 NOS1 NOS3 PRL
17 malignant secondary hypertension 10.3 EDN1 KNG1
18 androgenic alopecia 10.3 KLK3 PRL SHBG
19 diffuse scleroderma 10.3 EDN1 KNG1
20 reproductive system disease 10.3 KLK3 PRL SHBG
21 breast disease 10.3 KLK3 PRL SHBG
22 acute chest syndrome 10.2 EDN1 NOS1 NOS3
23 prostatitis 10.2
24 coronary artery vasospasm 10.2 EDN1 KNG1 NOS3
25 acquired metabolic disease 10.2 NOS3 PRL SHBG
26 persistent fetal circulation syndrome 10.2 EDN1 NOS3 PDE5A
27 ischemic optic neuropathy 10.2 EDN1 NOS3 PDE5A
28 nonarteritic anterior ischemic optic neuropathy 10.2 EDN1 NOS3 PDE5A
29 arteries, anomalies of 10.1 EDN1 KNG1 NOS3
30 hepatopulmonary syndrome 10.1 EDN1 NOS2 NOS3
31 orthostatic intolerance 10.1 EDN1 NOS2 NOS3
32 peyronie's disease 10.1
33 urethritis 10.1
34 infertility 10.1
35 jejunoileitis 10.0 ALDH7A1 NOS1 NOS3
36 prostate cancer 10.0
37 chronic mountain sickness 10.0 EDN1 NOS3
38 retinitis pigmentosa 19 10.0 ALDH7A1 KCNMA1
39 diabetes mellitus 10.0
40 coronary artery anomaly 10.0 EDN1 KNG1 NOS3
41 androgen insensitivity, partial 9.9 SHBG SRD5A1
42 aging 9.9
43 endotheliitis 9.9
44 eisenmenger syndrome 9.9 EDN1 VIP
45 ischemia 9.9 EDN1 KNG1 NOS2 NOS3
46 aneurysm 9.9
47 hypertension, essential 9.9 EDN1 KNG1 NOS2 NOS3
48 pre-eclampsia 9.9 EDN1 KNG1 NOS2 NOS3
49 scleroderma, familial progressive 9.8
50 asthma 9.8

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


unable to perform sex, inability to maintain erection, equilibration disorder, symptom/complaint potency (excluding p07 p08), tremor, pelvic pain, angina pectoris

MGI Mouse Phenotypes related to Impotence:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.23 KCNMA1 NOS1 NOS2 NOS3 PDE3A PRL

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
3
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
5
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
6
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
7
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2 164656-23-9 6918296 152945
8
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 745-65-3 149351
9
Nitric Oxide Approved Phase 4 10102-43-9 145068
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
12
Udenafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 268203-93-6 6918523
13
Curcumin Approved, Investigational Phase 4 458-37-7 969516
14
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
15
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
16
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
19
Magnesium oxide Approved Phase 4 1309-48-4 14792
20
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
21
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
22
Rosiglitazone Approved, Investigational Phase 4,Phase 1 122320-73-4 77999
23
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
24
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
25 tannic acid Approved, Nutraceutical Phase 4,Phase 3
26
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 77-92-9 311
27
Allantoin Approved, Nutraceutical Phase 4 97-59-6 204
28
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
29 Orange Approved, Nutraceutical Phase 4
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
31
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
32
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
33 Anabolic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
34 Androgens Phase 4,Phase 3,Phase 2,Early Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Early Phase 1
40
Testosterone enanthate Phase 4,Phase 3,Phase 2,Early Phase 1 315-37-7 9416
41 Testosterone undecanoate Phase 4,Phase 3,Phase 2,Early Phase 1
42 Vardenafil Dihydrochloride Phase 4,Phase 3,Phase 2,Phase 1
43 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Liver Extracts Phase 4
47 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Adrenergic Agonists Phase 4,Phase 1,Phase 2
49 Adrenergic beta-Agonists Phase 4,Phase 1,Phase 2
50 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 499)

# Name Status NCT ID Phase Drugs
1 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
2 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Nebivolol Effects on Endothelial Function and Erectile Function Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
5 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
6 Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
7 Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
8 Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Unknown status NCT00313898 Phase 4 sildenafil (viagra)
9 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
10 Treatment of Hyperlipidemia and Sexual Dysfunction Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
11 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied Completed NCT00301262 Phase 4 Viagra (Sildenafil citrate)
12 A Study in Patients With Erectile Dysfunction Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
13 Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction Completed NCT00664833 Phase 4
14 L-Arginine and Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
15 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction Completed NCT00422578 Phase 4 tadalafil
16 Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED) Completed NCT00665340 Phase 4 Placebo;Levitra (Vardenafil, BAY38-9456)
17 Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
18 Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)
19 Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia Completed NCT00663845 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
20 Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
21 Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00681772 Phase 4 Levitra (Vardenafil, BAY38-9456)
22 Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED) Completed NCT01153204 Phase 4 Sildenafil citrate
23 Mild To Moderate Erectile Dysfunction Study Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
24 Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes. Completed NCT01180283 Phase 4 lodenafil carbonate
25 Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
26 BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
27 A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China Completed NCT01352507 Phase 4 Tadalafil;Sildenafil
28 Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels Completed NCT00199563 Phase 4 Viagra
29 Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
30 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
31 A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
32 Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
33 A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction Completed NCT02224846 Phase 4 Tadalafil
34 A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
35 QEQ Treatment Responsiveness Evaluation Study Completed NCT00151463 Phase 4 sildenafil citrate
36 Quality of Erection Study Completed NCT00159900 Phase 4 Sildenafil Citrate
37 Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED) Completed NCT00663130 Phase 4 Levitra (Vardenafil, BAY38-9456);Tadalafil
38 Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
39 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00644631 Phase 4 sildenafil;placebo
40 Effect of Testosterone in Men With Erectile Dysfunction Completed NCT00512707 Phase 4 Sildenafil citrate (open label);Testosterone gel
41 A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction. Completed NCT00468650 Phase 4 sildenafil citrate
42 A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil Completed NCT00644956 Phase 4 tadalafil;sildenafil
43 A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
44 Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients Completed NCT01468519 Phase 4 Insulin;Insulin
45 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
46 A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil Completed NCT01108900 Phase 4 sildenafil
47 A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis Completed NCT00654017 Phase 4 placebo;sildenafil
48 Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Completed NCT00667979 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
49 A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy. Completed NCT00668096 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
50 The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction Completed NCT02413099 Phase 4 KBMSI-2

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Impotence

Genetic tests related to Impotence:

# Genetic test Affiliating Genes
1 Impotence 28

Anatomical Context for Impotence

MalaCards organs/tissues related to Impotence:

38
Prostate, Spinal Cord, Bone, Testes, Kidney, Endothelial, Liver

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 581)
# Title Authors Year
1
The Magic Pill: The Branding of Impotence and the Positioning of Viagra as Its Solution through Edutainment. ( 29436964 )
2018
2
Impotence after Radical Prostatectomy. ( 28010984 )
2017
3
Measurement of electrochemical conductance of penile skin using Sudoscan(Ar): A new tool to assess neurogenic impotence. ( 28528745 )
2017
4
Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. ( 28012765 )
2017
5
Potent Phosphodiesterase Inhibition and Nitric Oxide Release Stimulation of Anti-Impotence Thai Medicinal Plants from "MANOSROI III" Database. ( 28811831 )
2017
6
Quality analysis of randomized controlled trials in the International Journal of Impotence Research: quality assessment and relevant clinical impact. ( 27904149 )
2016
7
Baseline status and dose to the penile bulb predict impotence 1A year after radiotherapy for prostate cancer. ( 27079673 )
2016
8
At a Loss for Words: Nosological Impotence in the Search for Justice. ( 26944742 )
2016
9
Omnipotence and Impotence: The Need for Conversation When Patients and Clinicians Disagree. ( 27366844 )
2016
10
Infertility, impotence, and emasculation - psychosocial contexts for abandoning reproduction. ( 26924280 )
2016
11
Half a Man: The Symbolism and Science of Paraplegic Impotence in World War II America. ( 27066626 )
2015
12
Does impotence improve afterA parathyroidectomy in men withA primary hyperparathyroidism? ( 26492988 )
2015
13
Alprostadil for the treatment of impotence. ( 24369066 )
2014
14
Impotence: a frustratingly elusive target. ( 24857943 )
2014
15
Impotence due to external iliac steal syndrome: treatment with percutaneous transluminal angioplasty and stent placement. ( 23323034 )
2013
16
On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned? ( 23807950 )
2013
17
Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. ( 23219214 )
2013
18
Office-based management of impotence and Peyronie's disease. ( 24182973 )
2013
19
The role of interventional radiology in the diagnosis and management of male impotence. ( 23188557 )
2013
20
The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. ( 20884073 )
2011
21
Lue TF, Zeineh SJ, Scmidt RA and Tanagho EA--Neuroanatomy of penile erection: its relevance to iatrogenic impotence. 1984. ( 21284826 )
2011
22
Humanity, what will you choose-ominous impotence or omnipotence? ( 21191535 )
2010
23
Transurethral resection of the prostate stands accused of causing impotence in patients: should it be found culpable? ( 20394617 )
2010
24
The role of Doppler ultrasound in the diagnosis of vasculogenic impotence. ( 21341552 )
2010
25
Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. ( 20565373 )
2010
26
Further experience with an operation for the cure of certain types of impotence. O.S. Lowsley, and A. Rueda. ( 19682228 )
2009
27
Nocturnal erections, differential diagnosis of impotence, and diabetes. I Karacan, FB Scott, PJ Salis, SL Attia, JC Ware, A Altinel, and RL Williams. ( 19215613 )
2009
28
Is intracavernous injection of papaverine a reliable screening test for vascular impotence? J. Buvat, M. Herbaut-Buvat, J.L. Dehaene, and A. Lemaire. ( 20092548 )
2009
29
Impotence in the 18th and 19th century: concepts of etiology and approaches to therapy. ( 20013735 )
2009
30
Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence. ( 19554009 )
2009
31
Management of erectile impotence: use of inflatable prosthesis. ( 19006495 )
2008
32
Direct arterial anastomosis on corpora cavernosal penis in the therapy of erectile impotence. V. Michal, R. Kramar, j. Pospichal, and L. Hejhal. 1973. ( 18439152 )
2008
33
Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. ( 18774989 )
2008
34
Decreased ecto-NTPDase1/CD39 activity leads to desensitization of P2 purinoceptors regulating tonus of corpora cavernosa in impotent men with endothelial dysfunction. ( 18600538 )
2008
35
Impotence and libido in Arabic medical literature. ( 18792558 )
2008
36
Alternate-day tadalafil in the management of honeymoon impotence. ( 18208502 )
2008
37
Impotence and suing for sex in eighteenth-century England. ( 18342192 )
2008
38
Transient impotence after transrectal ultrasound-guided prostate biopsy. ( 17924579 )
2008
39
Thalidomide induced impotence in male hematology patients: a common but ignored complication? ( 18024384 )
2007
40
Curing prostate cancer--without surgery. Combo radiation therapies enable prostate retention, low risk of incontinence and impotence. ( 17441276 )
2007
41
The impotence of being important--reflections on leadership. ( 17548855 )
2007
42
Vasculogenic impotence as a symptom in late-onset Buerger's disease. ( 17486572 )
2007
43
Management of honeymoon impotence. ( 16490033 )
2006
44
On call. Whenever I ride my bike for more than an hour or so, I notice numbness in my penis. I know that can lead to impotence, so I've stopped taking long rides. But now I see some policemen in my town patrolling on bikes all day long. Will they end up with problems? ( 17288024 )
2006
45
Relationship between nocturnal penile tumescence parameters, International Index of Erectile Function symptom scores and sildenafil responses1This paper was presented at the 6th Congress of the International Society of Sexual and Impotence Research, Buenos Aires, Argentina, 17-21 October 2004. ( 17130103 )
2006
46
An herbal remedy for impotence: more than was bargained for. ( 17050803 )
2006
47
The impotence of cumulative effects assessment in Canada: ailments and ideas for redeployment. ( 16362488 )
2006
48
HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. ( 16454541 )
2006
49
Enhanced thromboxane receptor-mediated responses and impaired endothelium-dependent relaxation in human corpus cavernosum from diabetic impotent men: role of protein kinase C activity. ( 16888082 )
2006
50
Tobacco education: emphasizing impotence as a consequence of smoking. ( 17158700 )
2006

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 KCNMA1 KNG1 NOS1 NOS2 NOS3 PDE3A
2
Show member pathways
12.35 EDN1 NOS1 NOS2 NOS3
3
Show member pathways
12.01 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
4 11.85 NOS1 NOS2 NOS3
5 11.69 EDN1 NOS2 NOS3
6
Show member pathways
11.42 NOS1 NOS2 NOS3
7
Show member pathways
11.31 ALDH7A1 ARG2 NOS1 NOS2 NOS3
8
Show member pathways
11.23 NOS1 NOS2 NOS3
9 11.06 NOS1 NOS2 NOS3
10
Show member pathways
11.04 ARG2 NOS1 NOS2 NOS3
11 10.96 NOS1 NOS2 NOS3
12
Show member pathways
10.72 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
13 10.45 NOS1 NOS2 NOS3
14 10.37 NOS1 NOS2 NOS3 PDE5A

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 caveola GO:0005901 8.8 KCNMA1 NOS1 NOS3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.99 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1
2 response to hypoxia GO:0001666 9.76 EDN1 KCNMA1 NOS1 NOS2
3 cell redox homeostasis GO:0045454 9.72 NOS1 NOS2 NOS3
4 striated muscle contraction GO:0006941 9.62 ARG2 NOS1
5 positive regulation of blood vessel diameter GO:0097755 9.62 NOS2 NOS3
6 positive regulation of cardiac muscle hypertrophy GO:0010613 9.61 EDN1 PDE5A
7 regulation of sodium ion transport GO:0002028 9.61 NOS1 NOS3
8 negative regulation of blood pressure GO:0045776 9.61 NOS1 NOS2 NOS3
9 androgen metabolic process GO:0008209 9.6 CYP3A4 SRD5A1
10 negative regulation of blood coagulation GO:0030195 9.59 EDN1 KNG1
11 negative regulation of calcium ion transport GO:0051926 9.58 NOS1 NOS3
12 exogenous drug catabolic process GO:0042738 9.58 CYP3A4 NOS1
13 negative regulation of potassium ion transport GO:0043267 9.57 NOS1 NOS3
14 body fluid secretion GO:0007589 9.56 EDN1 VIP
15 negative regulation of hydrolase activity GO:0051346 9.54 NOS1 NOS3
16 vasodilation GO:0042311 9.54 KNG1 NOS1 NOS3
17 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.52 EDN1 NOS3
18 regulation of blood vessel size GO:0050880 9.5 EDN1 KNG1 NOS3
19 diterpenoid metabolic process GO:0016101 9.49 PDE3A SRD5A1
20 peptidyl-cysteine S-nitrosylation GO:0018119 9.48 NOS1 NOS2
21 nitric oxide mediated signal transduction GO:0007263 9.43 NOS1 NOS2 NOS3
22 positive regulation of oocyte development GO:0060282 9.4 PDE3A PDE5A
23 positive regulation of guanylate cyclase activity GO:0031284 9.33 NOS1 NOS2 NOS3
24 arginine catabolic process GO:0006527 9.13 NOS1 NOS2 NOS3
25 nitric oxide biosynthetic process GO:0006809 8.92 ARG2 NOS1 NOS2 NOS3

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1
2 iron ion binding GO:0005506 9.76 CYP3A4 NOS1 NOS2 NOS3
3 heme binding GO:0020037 9.71 CYP3A4 NOS1 NOS2 NOS3
4 hormone activity GO:0005179 9.7 EDN1 PRL VIP
5 flavin adenine dinucleotide binding GO:0050660 9.67 NOS1 NOS2 NOS3
6 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.54 PDE3A PDE5A
7 NADP binding GO:0050661 9.54 NOS1 NOS2 NOS3
8 3,5-cyclic-GMP phosphodiesterase activity GO:0047555 9.51 PDE3A PDE5A
9 FMN binding GO:0010181 9.5 NOS1 NOS2 NOS3
10 cadmium ion binding GO:0046870 9.48 NOS1 NOS3
11 arginine binding GO:0034618 9.43 NOS1 NOS2 NOS3
12 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS1 NOS2 NOS3
13 tetrahydrobiopterin binding GO:0034617 9.13 NOS1 NOS2 NOS3
14 nitric-oxide synthase activity GO:0004517 8.8 NOS1 NOS2 NOS3

Sources for Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....